162 related articles for article (PubMed ID: 37945451)
1. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
Miszczyk M; Rajwa P; Yanagisawa T; Nowicka Z; Shim SR; Laukhtina E; Kawada T; von Deimling M; Pradere B; Rivas JG; Gandaglia G; van den Bergh RCN; Goldner G; Supiot S; Zilli T; Trinh QD; Nguyen PL; Briganti A; Ost P; Ploussard G; Shariat SF
Eur Urol; 2024 Feb; 85(2):125-138. PubMed ID: 37945451
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
3. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
4. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
7. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
8. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
9. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
11. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
12. Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.
de Barros HA; van Beurden I; Droghetti M; Wilthagen EA; Özman O; Bergman AM; Aluwini S; van Moorselaar RJA; Donswijk ML; van Leeuwen PJ; van der Poel HG
Eur Urol Oncol; 2023 Feb; 6(1):16-27. PubMed ID: 36372736
[TBL] [Abstract][Full Text] [Related]
13. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
16. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
18. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
19. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Parikh NR; Chang EM; Nickols NG; Rettig MB; Raldow AC; Steinberg ML; Koontz BF; Vapiwala N; Deville C; Feng FY; Spratt DE; Reiter RE; Phillips R; Ost P; Tran PT; Kishan AU
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):917-926. PubMed ID: 32544574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
